Sep 07, 2023 4:14pm EDT Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
Aug 01, 2023 7:59am EDT Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function
Jul 20, 2023 8:43am EDT Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash
Jul 20, 2023 8:40am EDT Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.
Jun 30, 2023 9:28am EDT Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors
Jun 06, 2023 4:30pm EDT Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
Jun 01, 2023 7:57am EDT Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
May 03, 2023 8:26am EDT Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
Mar 02, 2023 8:00am EST Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
